CRISM Therapeutics Corporation (LON:CRTX) Insider Gerald Beaney Buys 20,182 Shares

CRISM Therapeutics Corporation (LON:CRTX) insider Gerald Beaney acquired 20,182 shares of the stock in a transaction dated Monday, April 7th. The stock was acquired at an average cost of GBX 988 ($12.74) per share, with a total value of £199,398.16 ($257,022.63).

CRISM Therapeutics Trading Up 1.4 %

CRTX stock traded up GBX 0.11 ($0.00) during mid-day trading on Monday, reaching GBX 8.11 ($0.10). The company’s stock had a trading volume of 21,436 shares, compared to its average volume of 24,273. CRISM Therapeutics Corporation has a 12 month low of GBX 5 ($0.06) and a 12 month high of GBX 30.90 ($0.40). The business’s 50 day moving average price is GBX 7.26 and its 200 day moving average price is GBX 8.81. The company has a market cap of £883,524.59, a price-to-earnings ratio of -1.40 and a beta of 0.81.

CRISM Therapeutics Company Profile

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.
ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour.